HC Wainwright Forecasts Strong Price Appreciation for Viridian Therapeutics (NASDAQ:VRDN) Stock

Viridian Therapeutics (NASDAQ:VRDN) had its price target increased by stock analysts at HC Wainwright from $22.00 to $40.00 in a research report issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright‘s price objective would indicate a potential upside of 40.40% from the stock’s current price. HC Wainwright also issued estimates for Viridian Therapeutics’ Q4 2027 earnings at ($0.16) EPS.

Several other equities research analysts have also recently commented on the stock. Royal Bank Of Canada lifted their price target on shares of Viridian Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 22nd. Needham & Company LLC raised their price objective on shares of Viridian Therapeutics from $34.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday. Truist Financial lifted their target price on shares of Viridian Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Weiss Ratings upgraded shares of Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 14th. Finally, Wall Street Zen downgraded Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, October 4th. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $41.00.

Viridian Therapeutics Trading Down 0.2%

Viridian Therapeutics stock traded down $0.06 during mid-day trading on Thursday, hitting $28.49. The stock had a trading volume of 4,487,163 shares, compared to its average volume of 2,101,929. The stock has a 50-day simple moving average of $21.97 and a two-hundred day simple moving average of $21.81. The stock has a market capitalization of $3.23 billion, a PE ratio of -7.42 and a beta of 1.07. Viridian Therapeutics has a 12 month low of $13.18 and a 12 month high of $34.29. The company has a current ratio of 16.95, a quick ratio of 16.95 and a debt-to-equity ratio of 0.43.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.21. Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%. The firm had revenue of $25.75 million during the quarter, compared to analysts’ expectations of $4.72 million. As a group, sell-side analysts forecast that Viridian Therapeutics will post -3.94 EPS for the current year.

Insider Activity at Viridian Therapeutics

In other news, insider Jennifer Tousignant sold 14,212 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total value of $348,194.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of VRDN. Parkman Healthcare Partners LLC bought a new stake in Viridian Therapeutics in the second quarter valued at approximately $25,306,000. Rice Hall James & Associates LLC bought a new position in shares of Viridian Therapeutics during the second quarter worth $21,601,000. Elmind Capital LP bought a new position in shares of Viridian Therapeutics during the second quarter worth $18,093,182. Bank of America Corp DE acquired a new position in shares of Viridian Therapeutics in the 2nd quarter valued at $17,348,000. Finally, Deutsche Bank AG acquired a new position in shares of Viridian Therapeutics in the 2nd quarter valued at $8,870,000.

Key Headlines Impacting Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Viridian reported a third-quarter loss of $0.81 per share, narrower than analysts’ roughly $1.02-per-share estimate. The earnings beat, alongside optimism around the Lumvoa launch, has supported investor interest. Viridian Therapeutics Stock Rises 5% Despite Wider Q3 Loss
• Positive Sentiment: Analysts raised targets and maintained bullish ratings. Recent increases include Leerink Partners to $54, RBC to $41, Truist to $42, Wells Fargo to $34, Wedbush to $42 and HC Wainwright to $40. Zacks also noted a positive trend in earnings estimate revisions, though price targets are not guarantees. Zacks analyst outlook
• Neutral Sentiment: The company will present Phase 1 results for VRDN-008 and outline plans for its FcRn portfolio on November 9. The data and development plans could provide meaningful signals about the pipeline, but the outcome is not yet known. VRDN-008 conference call announcement

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.